Our Pricing

How to Begin Mounjaro WEIGHTLOSSNEW Code

Published on: June 03, 2026

Searching for guidance on the mounjaro weightlossnew code UK and how to start your treatment journey? At Cured Pharmacy, we provide transparent pricing on genuine UK-licensed Mounjaro from £124.99, with a free clinical consultation completed in under three minutes and discreet next-day delivery across the UK.

Understanding Mounjaro WEIGHTLOSSNEW Code Access in the UK

When beginning Mounjaro treatment in the UK, patients often search for promotional codes or discount programmes to reduce the cost of this prescription-only medication. At Cured Pharmacy, we maintain transparent upfront pricing on all weight loss treatments, ensuring you know the exact cost before completing your clinical assessment. Mounjaro (tirzepatide) is available from £124.99, representing competitive UK pricing without hidden fees or consultation charges [1].

All Mounjaro prescriptions require assessment by a UK-registered prescriber, regardless of any promotional code. Our clinical team evaluates your medical history, current medications, and weight loss goals to determine whether Mounjaro is appropriate for you. This regulatory requirement protects patient safety and ensures compliance with MHRA guidelines for prescription-only medicines [2].

The WEIGHTLOSSNEW code enquiry typically reflects patients' desire to access tirzepatide treatment at the most affordable rate possible. Our pharmacy guarantees the lowest prices in the UK on genuine, licensed medications, with all costs displayed transparently before you begin your consultation. There are no surprise charges at checkout, and our superintendent pharmacist Tarun Kumar (GPhC 2233073) personally oversees dispensing quality.

How Mounjaro Works: Dual GIP/GLP-1 Mechanism

Mounjaro contains tirzepatide, the first dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed for weight management in the UK [1]. This dual-action mechanism distinguishes it from single-pathway treatments like semaglutide, targeting two complementary hormone systems that regulate appetite, food intake, and glucose metabolism.

In the landmark SURMOUNT-1 trial, participants receiving the 15mg maintenance dose of tirzepatide achieved an average body weight reduction of 22.5% over 72 weeks—significantly greater than results observed with single GLP-1 agonists in comparable studies [1][3]. The dual receptor activation produces enhanced satiety signals, reduced hunger, and improved glycaemic control, making it particularly effective for patients with obesity and metabolic complications.

Tirzepatide works by mimicking natural incretin hormones released after eating. The GIP component enhances insulin secretion and may influence fat metabolism, whilst the GLP-1 component slows gastric emptying, reduces appetite, and promotes feelings of fullness. This combined effect helps patients achieve substantial, sustained weight loss when used alongside dietary modifications and increased physical activity [3].

Expected Results and Timeline

Clinical trials demonstrate that most patients begin experiencing appetite reduction within the first two weeks of starting Mounjaro, with measurable weight loss typically evident by week four [1]. The treatment follows a dose-escalation protocol, starting at 2.5mg weekly and gradually increasing every four weeks to minimise gastrointestinal side effects whilst optimising efficacy. Your UK prescriber will determine the appropriate maintenance dose based on your response and tolerability, with options ranging from 5mg to 15mg weekly.

Starting Your Mounjaro Treatment: The Complete UK Process

Beginning Mounjaro treatment through Cured Pharmacy involves a straightforward three-step process designed to meet UK regulatory requirements whilst providing convenient access. First, complete our free online clinical consultation, which takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications. Our UK-registered prescribers review every assessment individually—there are no automated approvals.

If Mounjaro is deemed clinically appropriate, your prescription is issued electronically and sent directly to our dispensary. We source all medications from licensed UK wholesalers and manufacturers, ensuring you receive genuine Mounjaro KwikPens in their original packaging. Your treatment is dispatched via tracked courier in 100% discreet packaging, typically arriving the next working day across mainland UK.

Your first prescription will include the 2.5mg starter dose, as per MHRA-approved prescribing guidelines. After four weeks, you'll complete a follow-up consultation to assess tolerability and progress before escalating to the 5mg dose. This gradual titration continues every four weeks until you reach your optimal maintenance dose, which your prescriber determines based on weight loss response and side effect profile [2].

What to Expect During Your First Month

During the initial four weeks on the 2.5mg starter dose, most patients notice reduced appetite and early changes in eating behaviour. Some experience mild gastrointestinal effects such as nausea or altered bowel habits as the body adjusts to the medication. These side effects typically diminish within two to three weeks and are less pronounced with the gradual dose escalation protocol. Staying well-hydrated and eating smaller, more frequent meals can help minimise discomfort during this adjustment period.

Mounjaro Pricing and UK Availability at Cured Pharmacy

Mounjaro is available at Cured Pharmacy from £124.99, with transparent pricing displayed before you begin your consultation. This represents the total cost per four-week supply, with no hidden consultation fees, prescription charges, or delivery costs added at checkout. We guarantee the lowest prices in the UK on genuine, licensed weight loss medications, and our pricing structure remains consistent regardless of promotional enquiries.

The cost of Mounjaro varies depending on your prescribed maintenance dose. The 2.5mg and 5mg starter doses are priced lower than the 10mg and 15mg maintenance strengths, reflecting the different quantities of active ingredient. Your UK prescriber will determine the most appropriate dose based on your clinical response, and you'll always see the exact price for your specific prescription before confirming your order.

Unlike some online pharmacies that advertise low prices but add consultation fees or membership charges, Cured Pharmacy maintains fully transparent pricing. The amount you see on our product page is the complete cost you'll pay, with free standard delivery included. We're a UK-registered pharmacy (GPhC 9012511) dispensing only MHRA-licensed medications, ensuring you receive authentic Mounjaro at the most competitive rate available.

Mounjaro vs Alternative Weight Loss Treatments

When considering weight loss medication in the UK, patients often compare Mounjaro with alternative treatments such as Wegovy (semaglutide) and Saxenda (liraglutide). Whilst all three are GLP-1-based injectable medications licensed by the MHRA, they differ in mechanism, dosing frequency, and clinical efficacy. Mounjaro's dual GIP/GLP-1 action typically produces greater weight loss than single-pathway alternatives in head-to-head comparisons [3][4].

Wegovy contains semaglutide, a single GLP-1 receptor agonist administered once weekly. In the STEP trials, semaglutide 2.4mg produced an average weight loss of 14.9% over 68 weeks—substantial results, but lower than the 22.5% average observed with tirzepatide 15mg in SURMOUNT-1 [3][4]. Both medications require similar dose escalation protocols and carry comparable side effect profiles, primarily gastrointestinal in nature.

Saxenda (liraglutide) requires daily injections rather than weekly administration, which some patients find less convenient. Clinical trials showed average weight loss of approximately 8% with liraglutide 3mg daily, making it effective but generally less potent than newer weekly alternatives [4]. Your UK prescriber will consider factors including your weight loss goals, medical history, previous treatment responses, and personal preferences when recommending the most suitable option.

For patients who cannot tolerate injectable medications or prefer oral treatments, options include Orlistat (a fat absorption inhibitor) and Mysimba (a combination of naltrexone and bupropion). These produce more modest weight loss—typically 5-10%—but may suit patients with needle phobia or specific contraindications to GLP-1 therapies. All prescription weight loss medications available through Cured Pharmacy require clinical assessment by a UK prescriber to ensure safety and appropriateness.

Choosing Between Mounjaro and Wegovy

The choice between Mounjaro and Wegovy often comes down to clinical efficacy expectations, cost considerations, and individual response. Mounjaro typically produces greater weight loss in clinical trials, but Wegovy has been available longer and has extensive real-world safety data. Some patients find one medication better tolerated than the other. Your prescriber can guide you through this decision based on your specific circumstances, and it's possible to switch between treatments if your initial choice doesn't produce the desired results or causes problematic side effects.

Safety, Side Effects, and Ongoing Monitoring

Mounjaro is generally well-tolerated, but like all prescription medications, it can cause side effects. The most common are gastrointestinal, including nausea (occurring in approximately 20-30% of patients), diarrhoea, constipation, and reduced appetite [1]. These effects are typically mild to moderate, most pronounced during dose escalation, and diminish over time as your body adjusts to the medication.

More serious but rare side effects include pancreatitis, gallbladder problems, and thyroid C-cell tumours (observed in animal studies but not conclusively linked in humans). Mounjaro is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 [2]. Your UK prescriber will screen for these contraindications during your consultation and monitor you throughout treatment.

Ongoing monitoring is essential when taking Mounjaro. You'll complete follow-up consultations every four weeks during dose escalation, then at regular intervals once you reach your maintenance dose. These reviews assess weight loss progress, side effect management, and any changes to your medical circumstances. If you experience severe abdominal pain, persistent vomiting, or signs of pancreatitis, stop taking Mounjaro immediately and seek medical attention.

Mounjaro should be used as part of a comprehensive weight management programme that includes dietary modifications and increased physical activity. Clinical trials demonstrating significant weight loss all involved participants who also made lifestyle changes [1][3]. Your prescriber may recommend working with a dietitian or weight management specialist to optimise your results and develop sustainable habits that support long-term weight maintenance after completing treatment.

Who Should Not Take Mounjaro

Mounjaro is not suitable for everyone. It's contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe gastrointestinal disease, or a history of medullary thyroid carcinoma. Pregnant or breastfeeding women should not take Mounjaro, and women of childbearing age should use effective contraception during treatment. Patients with severe renal impairment or a history of pancreatitis require careful assessment before starting tirzepatide. Your UK prescriber will evaluate all contraindications and precautions during your consultation to ensure Mounjaro is safe for you.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
3. Ludvik, B., Giorgino, F., Jódar, E., et al. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet, 398(10300), 583–598. https://doi.org/10.1016/S0140-6736(21)01443-4 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence, lifestyle modifications, and metabolic response.